Остеонекроз. Часть 1. Факторы риска и патогенез
Аннотация
Литература
1. <div><p>Felson D.T., Zhang Y., Hannan M.T. et al. The incidence and natural history of knee osteoarthritis in the elderly. Arthr Rheum 1995;38:1500—5.</p><p>Kellgren J.H., Lawrence J.S. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957;16:494-502.</p><p>Calder J.D., Buttery L., Revell P.A. et al.Apoptosis — a significant cause of bone cell death in osteonecrosis of the femoral head. J Bone Joint Surg Br 2004; 86:1209-13.</p><p>Weinstein R.S., Nicholas R.W., Manolagas S.C. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000; 85:2907-12.</p><p>Youm Y.S., Lee S.Y., Lee S.H. Apoptosis in the osteonecrosis of the femoral head. Clin Orthop Surg 2010;2:250-5.</p><p>Bejar J., Peled E., Boss J.H. Vasculature deprivation — induced osteonecrosis of the rat femoral head as a model for therapeutic trials. Theor Biol Med Model 2005;2:24.</p><p>Sacamoto M., Shimizu K., Iida S. et al. Osteonecrosis of the femoral head. J Bone Joint Surg Br 1997;79:213-9.</p><p>Malizos K.N., Karantanas A.H., Varitimidis S.E. et al. Osteonecrosis of the femoral head: etiology, imaging and treatment. Eur J Radiol 2007;63(1):16—28.</p><p>Mont M.A., Hungerford D.S. Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am 1995;77(3):459-74.</p><p>Vail T.P., Covington D.M. The incidence of osteonecrosis. In: Osteonecrosis: Etiology, Diagnosis, and Treatment. J.R. Urbaniak, J.P. Jones Jr. (eds). Rosemont, IL: American Academy of Orthopedic Surgeons, 1997;43—9.</p><p>Larson A.N., McIntosh A.L., Trousdale R.T., Lewallen D.G. Avascular necrosis most common indication for hip arthroplasty in patients with slipped capital femoral epiphysis. J Pediatr Orthop 2010;30(8):767—73.</p><p>Luedtke L.M., Flynn J.M., Pill S.G. A review of avascular necrosis in developmental dysplasia of the hip and contemporary efforts at prevention. UPOJ 2000;13:22-8.</p><p>Mont M.A., Zywiel M.G., Marker D.R. et al. The natural history of untreated asymptomatic osteonecrosis of the femoral head: a systematic literature review. J Bone Joint Surg Am 2010;92(12):2165—70.</p><p>Morse C.G., Mican J.M., Jones E.C. et al. The incidence and natural history of osteonecrosis in HIV-infected adults. Clin Infect Dis2007;44(5):739-48.</p><p>Ono K., Sugioka Y. Epidemiology and risk factors in avascular necrosis of the femoral head. In: Bone circulation and vascularization in normal and pathological conditions. A. Schourens, J. Arlet, J.W.M. Gardeniers et al. (eds). New York, 1993:241-8.</p><p>Mankin H.J. Nontraumatic Necrosis of Bone (Osteonecrosis). N Engl J Med 1992;326:1473-9.</p><p>Ficat R.P. Idiopathic bone necrosis of the femoral head: early diagnosis and treatment. J Bone Joint Surg Br 1985;67:3-105.</p><p>Hungerford D.S., Lennox D.W. The importance of increased intraosseous pressure in the development of osteonecrosis of the femoral head: implications for treatment. Orthop Clin North Am 1985;16:635-54.</p><p>Hungerford D.S. Core decompression for the treatment of avascular necrosis of the femoral head. Semin Arthrop 1991;2:182-8.</p><p>Grose A.W., Gardner M.J., Sussmann P.S. et al. The surgical anatomy of the blood supply to the femoral head: description of the anastomosis between the medial femoral circumflex and inferior gluteal arteries at the hip. J Bone Joint Surg Br 2008;90:1298-303.</p><p>Lavernia C.J., Sierra R.J., Grieco F.R. Osteonecrosis of the femoral head. J Am Acad Orthop Surg 1999;74:250-61.</p><p>Malizos K.N., Karantanas A.H., Varitimidis S.E. et al. Osteonecrosis of the femoral head: etiology, imaging and treatment. Eur J Radiol 2007;63:16-28.</p><p>Jones J.P. Fat embolism, intravascular coagulation, and osteonecrosis. Clin Orthop Relat Res 1993;292:294-308.</p><p>Jones J.P. Jr. Etiology and pathogenesis of osteonecrosis. Semin Arthrop 1997; 2:182—8.</p><p>Cui Q., Wang G.J., Su C.C., Balian G. The Otto Aufranc Award. Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop Relat Res 1997;344:8-19.</p><p>Wang G.J., Sweet D.E., Reger S.I., Thompson R.C. Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J Bone Joint Surg Am 1977;59:729-35.</p><p>Kannu P., O'Rielly D.D., Hyland J.C., Kokko L.A. Avascular necrosis of the femoral head due to a novel C propeptide mutation in COL2A1. Am J Med Genet 2011;155A:1759-62.</p><p>Korompilias V.A., Ortel L.T., Urbaniak R.J. Coagulation abnormalities in patients with hip osteonecrosis. Orthop Clin N Am 2004;35:265-71.</p><p>Arruda V.R., Belangero W.D., Ozelo M.C. et al. Inherited risk factor for thrombophilia among children with Legg-Calve'-Perthes Disease. J Ped Orthop 1999;19:84-7.</p><p>Lykissas M.G., Gelalis I.D., Kostas-Agnantis I.P. The role of hypercoagulability in the development of osteonecrosis of the femoral head. Orthopedic Rev 2012;4:73-6.</p><p>Glueck C.J., Freiberg R., Glueck H.I. et al. Hybrofibrinolysis: а common, major cause of osteonecrosis. Am J Hematol 1994;45:156-66.</p><p>Glueck C.J., Freiberg R., Tracy T. et al. Thrombophilia and Hypofibrinolysis. Pathophysiologies of Osteonecrosis. Clin Orthop Relat Res 1997;334:43-56.</p><p>Glueck C.J., Fontaine R.N., Gruppo R. et al. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop Relat Res 1999;366:133-46.</p><p>Tan X., Cai D., Wu Y. et al. Comparative analysis of serum proteomes: discovery of proteins associated with osteonecrosis of the femoral head. Translational Res 2006;148:114-9.</p><p>Francis R. The protein C anticoagulant pathway and thrombosis. West J Med 1985;143:95-6.</p><p>Hirata T., Fujioka M., Takahashi K. et al. Low molecular weight phenotype of apolipoprotein(a) is a risk factor of corticosteroid-induced osteonecrosis of the femoral head after renal transplant. J Rheum 2007;34:516-22.</p><p>Fortmann S.P., Marcovina S.M. Lipoprotein(a), a clinically elusive lipoprotein particle. Circulation 1997;95:295-6.</p><p>Glueck C.J., Freiberg R., Glueck H.I. et al. Hybrofibrinolysis: а common, major cause of osteonecrosis.Am J Hematol 1994;45:156-66.</p><p>Mont M.A., Glueck C.J., Pacheco I.H. et al. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheum 1997;24:654-62.</p><p>Jones L.C., Mont M.A., Le T.B. et al. Procoagulants and osteonecrosis. J Rheum 2003;30:783-91.</p><p>Mudd S.H., Levy H.L., Skovby F. et al. The metabolic and molecular bases of inherited disease. V. 1. 7th ed. New York: McGraw-Hill. Disorders of transsulfuration, 1995;1279—327.</p><p>Mudd S.H., Skovby F., Levy H.L. et al. The natural history of homocystinuria due to cystathionine b-synthase deficiency. Am J Hum Genet 1985;37:1-31.</p><p>Holme E., Kjellman B., Ronge E. Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency. Arch Dis Child 1989;64:1061-4.</p><p>Fenton W.A., Rosenberg L.E., Scriver C.R. et al. The metabolic and molecular bases of inherited disease. V. 2. 7th ed. New York: McGraw-Hill. Inherited disorders of cobalamin transport and metabolism, 1995;3129—49.</p><p>Mandel H., Brenner B., Berant M. et al. Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis. N Engl J Med 1996;334:763-8.</p><p>Fuerer C., Nusse R., Ten Berge D. Wnt signaling in development and disease. Max Delbruck Center for Molecular Medicine meeting on Wnt signaling in Development and Disease. EMBO Rep 2008;9:134-8.</p><p>Gordon M.D., Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006;281:22429-33.</p><p>Logan C.Y., Nusse R. The Wnt signaling pathway in development and disease. Ann Rev Cell Dev Biol 2004;20:781-810.</p><p>Macdonald B.T., Semenov M.V., He X. SnapShot: Wnt/beta-catenin signaling. Cell 2007;131:1204.</p><p>Mikels A.J., Nusse R. Wnts as ligands: processing, secretion and reception. Oncogene 2006;25:7461-8.</p><p>Moon R.T., Brown J.D., Torres M. WNTs modulate cell fate and behavior during vertebrate development. Trends Genet 1997;13:157-62.</p><p>Nusse R. Wnt signaling and stem cell control. Cell Res 2008;18:523-7.</p><p>Semenov M.V., Habas R., Macdonald B.T., He X. SnapShot: Noncanonical Wnt Signaling Pathways.Cell 2007;131:1378.</p><p>Van Amerongen R., Mikels A., Nusse R. Alternative wnt signaling is initiated by distinct receptors. Sci Signal 2008;1:9.</p><p>Li J., Sarosi I., Cattley R.C. et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006;39:754-66.</p><p>Morvan F., Boulukos K., Clement-Lacroix P. et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006;21:934-45.</p><p>Tian E., Zhan F., Walker R. et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94.</p><p>Diarra D., Stolina M., Polzer K. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.</p><p>Uderhardt S., Diarra D., Katzenbeisser J. et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2010;69:592-7.</p><p>Lane N.E., Nevitt M.C., Lui L.Y. et al. Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. Arthr Rheum 2007;56:3319-25.</p><p>Lin C.L., Wang J.Y., Ko J.Y. et al. Dickkopf-1 Promotes Hyperglycemia-Induced Accumulation of Mesangial Matrix and Renal dysfunction. J Am Soc Nephrol 2010;21(1):124—35.</p><p>Cejka D., Herberth J., Branscum A.J. et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011;6(4):877-82.</p><p>Tаn Gang, Kang Peng-de, Pei Fu-xing. Glucocorticoids affect the metabolism of bone marrow stromal cells and lead to osteonecrosis of the femoral head: a review. Chin Med J 2012;125(1):134-9.</p><p>Ohnaka K. Wnt signaling and glucocorticoid-induced osteoporosis. Clin Calcium 2006;16(11):1812-6.</p><p>Glaw J.T., Skalak T.C., Peirce S.M. Inhibition of Canonical Wnt Signaling Increases Microvascular Hemorrhaging and Venular Remodeling in Adult Rats. Microcirculation 2010; 17(5):348—57.</p><p>Oinuma K., Harada Y., Hawata Y. et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 2001;60:1145-8.</p><p>Donoghue A.M. Bisphosphonates and osteonecrosis: analogy to phossy jaw. Med J 2005;183(3):163-4.</p><p>Shoback D. Update in osteoporosis and metabolic bone disorders.J Clin Endocrinol Metab 2007;92(3):747-53.</p><p>Bagan J.V., Jimenez Y., Diaz J.M. et al. Osteonecrosis of the jaws in intravenous bisphosphonate use: рroposal for a modification of the clinical classification. Oral Oncol2009;45:645-6.</p><p>Aghaloo T.L., Felsenfeld A.L., Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 2010;68:959-63.</p><p>Hess L.M., Jeter J.M., Benham-Hutchins M., Alberts D.S. Factors associated with osteonecrosis of the jaw among bisphosponate users. Am J Med 2008; 121(6):475-83.</p><p>Akamatsu Y., Mitsugi N., Hayashi T. et al. Low bone mineral density is associated with the onset of spontaneous osteonecrosis of the knee. Acta orthopaed 2012;83(3):249—55.</p></div><br />
Рецензия
Для цитирования:
Ilyinykh E.V., Барскова В.Г., Лидов П.И., Насонов Е.Л. Остеонекроз. Часть 1. Факторы риска и патогенез. Современная ревматология. 2013;7(1):17-24. https://doi.org/10.14412/1996-7012-2013-2362
For citation:
Ilyinykh E.V., Barskova V.G., Lidov P.I., Nasonov E.L. Osteonecrosis. Part 1. Risk factors and pathogenesis. Modern Rheumatology Journal. 2013;7(1):17-24. (In Russ.) https://doi.org/10.14412/1996-7012-2013-2362